In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some updates on the LocoMMotion study (NCT04035226). Prof. Einsele first discusses the overall survival (OS) and progression-free survival (PFS) observed, which further highlight the limited success of current treatment approaches and the importance of further investigating novel immunotherapies such as CAR-T therapy and bispecific antibodies in patients with relapsed/refractory (R/R) myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.